Cancer screening: a mathematical model relating secreted blood biomarker levels to tumor sizes.
about
Mathematical model identifies blood biomarker-based early cancer detection strategies and limitationsA strategy for blood biomarker amplification and localization using ultrasound.The preclinical natural history of serous ovarian cancer: defining the target for early detectionDNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines.Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by FluorescenceImpact of protein stability, cellular localization, and abundance on proteomic detection of tumor-derived proteins in plasma.Comparing the benefits of screening for breast cancer and lung cancer using a novel natural history model.Control values of ovarian cancer tumor markers and standardisation of a protocol for sampling peritoneal fluid and performing washing during laparoscopy.Disease detection by ultrasensitive quantification of microdosed synthetic urinary biomarkers.Serial analysis of 38 proteins during the progression of human breast tumor in mice using an antibody colocalization microarray.Tag-femtosecond laser-induced breakdown spectroscopy for the sensitive detection of cancer antigen 125 in blood plasma.Multifunctional core-shell nanoparticles: discovery of previously invisible biomarkers.Antibody colocalization microarray: a scalable technology for multiplex protein analysis in complex samples.Mathematical framework for activity-based cancer biomarkers.Simulation of the Protein-Shedding Kinetics of a Fully Vascularized Tumor.In-depth proteomics to define the cell surface and secretome of ovarian cancer cells and processes of protein sheddingPatient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.Point-of-care diagnostics for noncommunicable diseases using synthetic urinary biomarkers and paper microfluidics.Molecular signatures of ovarian cancer: from detection to prognosis.A Model-Based Personalized Cancer Screening Strategy for Detecting Early-Stage Tumors Using Blood-Borne Biomarkers.Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease.Screening for ovarian cancer: imaging challenges and opportunities for improvement.Synthetic Biomarker Design by Using Analyte-Responsive Acetaminophen.Design and development of a microarray processing station (MPS) for automated miniaturized immunoassays.Affinity enrichment for mass spectrometry: improving the yield of low abundance biomarkers.Turning the tide in lung cancer.Improving cancer detection through combinations of cancer and immune biomarkers: a modelling approach.Assessing the Diagnostic Value of Plasma-Free DNA in Prostate Cancer Screening
P2860
Q24614865-67E2F709-5914-4755-B3C6-DF894E804BF9Q24648447-5311D0B6-416E-423C-9238-56BDCB057F23Q33487678-D65DC90E-90D5-4FAD-8CD0-C464AA2BC18BQ33533746-737FAE54-2808-4F1A-9DAA-3263D0A23D57Q33759991-75B2AD29-9A31-4BBF-95E2-32207D1B9621Q33988224-3BD4626C-98E8-43D0-AE58-679C77A7D390Q34097395-8A024F13-9CE0-4BFF-9E89-5EF391C24616Q34204891-04CF6BAF-B5F6-45EC-A146-2B007E4A3A67Q34282732-E92938DD-C143-4009-99A8-CD5C437E1D35Q35325472-73737845-E31A-4A75-82B8-FC250F575965Q35541160-568E0D92-8028-4BDE-9793-88DBD15FED0CQ35571271-36F32AC8-91DC-4FF1-97F7-7E161359B6A5Q35878752-1615BC8C-2F85-4C21-BBED-27BB93233407Q36179245-99D01E0A-3064-4CCA-BF1E-03579F408154Q36395322-9BF9219A-1369-4B2C-BCD5-2CBF22E65235Q36485342-0D18904B-C796-4EA6-A775-E32C84066C03Q37383509-D84C0EA1-2CE4-467C-8DAE-7E695DB7CAB4Q37640983-8C84F55A-1015-4969-93C1-30E5132D1B51Q37685074-283E383D-4B38-4443-AD9F-8BAFEFD73A66Q38913999-A1E74D67-A1E3-4A85-9383-1154D5228601Q42682524-F3E5FF3B-6824-4AAF-BFDB-CC425A1E1C16Q43557526-3E278592-A7DC-4035-980E-894E9CFA841AQ48822089-148A986C-1566-458D-A2BB-4442154713B4Q51251811-892AE577-0A4B-4789-BA2D-DE4DDFA486B6Q52354794-BB988229-723F-4E48-802F-A8FA85A53E3AQ54643298-4077770E-4C4C-4322-825A-C712D521AFDBQ55297626-A3D1F7DD-274E-4DAB-B30C-6BB5938D3290Q58778276-6C1D0F88-6897-4F2F-98E3-81F132E27FF9
P2860
Cancer screening: a mathematical model relating secreted blood biomarker levels to tumor sizes.
description
2008 nî lūn-bûn
@nan
2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Cancer screening: a mathematic ...... omarker levels to tumor sizes.
@ast
Cancer screening: a mathematic ...... omarker levels to tumor sizes.
@en
type
label
Cancer screening: a mathematic ...... omarker levels to tumor sizes.
@ast
Cancer screening: a mathematic ...... omarker levels to tumor sizes.
@en
prefLabel
Cancer screening: a mathematic ...... omarker levels to tumor sizes.
@ast
Cancer screening: a mathematic ...... omarker levels to tumor sizes.
@en
P2093
P2860
P1433
P1476
Cancer screening: a mathematic ...... omarker levels to tumor sizes.
@en
P2093
Amelie M Lutz
Frank V Cochran
Pritha Ray
Sanjiv S Gambhir
P2860
P356
10.1371/JOURNAL.PMED.0050170
P407
P577
2008-08-01T00:00:00Z